Zacks Investment Research upgraded EndoChoice from a "hold" rating to a "buy" rating, according to a report by The HillTop News.
Here are four notes:
1. EndoChoice currently has a consensus rating of "buy" and an average target price of $16.31.
2. The company has a one-year low of $3.70 and a one-year high of $19.69.
3. The firm has a 50-day moving average of $5.03 and a 200-day moving average of $9.44.
4. EndoChoice's market capitalization is $117.28 million.